Acadia Pharmaceuticals | Les Charges D'Exploitation



Operating Expenses Changement Date
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
ALKERMES USD 267.3M 6.09M 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Corcept Therapeutics USD 156.63M 20.68M 2024-12
Cytokinetics USD 155.97M 14.7M 2024-12
Eisai JPY 188.58B 7.01B 2024-12
Eli Lilly USD 8.38B 1.53B 2024-12
Incyte USD 877.18M 114.6M 2024-12
J&J USD 18.63B 500M 2024-12
Moderna USD 2.21B 280M 2024-12
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Prothena USD 67.02M 463K 2024-12
PTC Therapeutics USD 275.66M 24.36M 2024-12
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Ultragenyx Pharmaceutical USD 287.15M 15.67M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Acadia Pharmaceuticals Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.